Pediatric safety and pharmacokinetic findings supported expanding leniolisib to children aged 4 to 11 years who weigh at least 27 kg, establishing the first FDA-approved treatment for activated...
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
At the August 2026 Practical Updates in Primary Care Virtual Meeting, Rakesh Jain, MD, MPH, and Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC, outlined a practical primary care approach to adult...
A randomized crossover trial examined whether N-of-1 deprescribing trials could identify older men receiving little symptomatic benefit from chronic tamsulosin therapy.
The FDA granted accelerated approval to Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for adults with multiple myeloma previously treated with a proteasome...
In a post-hoc analysis of a phase 3, open-label, 52-week LTE trial presented at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL., ubrogepant 100 mg showed consistent 2-hour pain...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, addressed migraine-related diagnosis, treatment, red flags, and care considerations across...
In this expert interview, W. Clay Jackson, MD, DipTh, discusses why deprescribing should be approached through shared decision-making, careful medication review, and attention to each patient’s current...
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
